What's Happening?
Moderna has received approval from the European Commission for its combination flu and COVID-19 vaccine, mCOMBRIAX, marking a significant regulatory win for the company. This approval allows the vaccine's use across all 27 EU member states, plus Iceland,
Liechtenstein, and Norway, for individuals aged 50 and above. The vaccine combines Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, with the investigational flu vaccine, mRNA-1010. Despite this success in Europe, Moderna has faced setbacks in the U.S., where it withdrew its application for the combo vaccine after discussions with the FDA.
Why It's Important?
The approval of mCOMBRIAX in Europe represents a critical milestone for Moderna, especially as it navigates regulatory challenges in the U.S. This development could bolster Moderna's position in the global vaccine market, potentially increasing its market share and revenue. The approval also underscores the differing regulatory landscapes between the EU and the U.S., highlighting the complexities pharmaceutical companies face in gaining approval across multiple jurisdictions. For the EU, this approval could enhance public health efforts by providing a dual-protection vaccine, especially for older populations.
What's Next?
Moderna is expected to focus on the rollout of mCOMBRIAX across Europe, subject to national regulatory and access procedures. In the U.S., the company is awaiting further guidance from the FDA regarding the resubmission of its combo vaccine application. The outcome of this process will be crucial for Moderna's strategy in the U.S. market. Additionally, the FDA's decision on the standalone mRNA-1010 flu vaccine, expected in August, will likely influence the future of the combo vaccine in the U.S.
